language_icon
EN
HI

Fredun Pharmaceuticals Share price

FREDUN

2100

0.85 (-0.04%)
Last updated on 29 Apr, 2026 | 15:29 IST
Today's High

2195.00

Today's Low

2038.00

52 Week Low

666.00

52 Week High

2200.00

Zero AMC

Free Demat with Zero AMC*

Open a Free Demat Account
+ Free 1st Year AMC

Fredun Pharmaceuticals Chart

Fredun Pharmaceuticals Share Key Metrics

Volume
9904.00
Market Cap
1000.35 CR
LTQ@LTP
30@2100.00
ATP
2094.32
Var Margin
22.22 %
Circuit Range
1680.7-2521
Delivery %
63.6 %
Value
2.07 CR
ASM/GSM
No
Market Lot
1

Summary

Fredun Pharmaceuticals share price stands at ₹2100 at 29 Apr, 2026 | 15:29. The stock Fredun Pharmaceuticals intraday movement has stayed between ₹2038.00 and ₹2195.00, while on a 52-week basis it has fluctuated from ₹666.00 to ₹2200.00.
In terms of trading activity, Fredun Pharmaceuticals has recorded a volume of 9904 shares. The Fredun Pharmaceuticals has a market cap of ₹4761662. The stock’s Average Traded Price (ATP) stands at ₹209432, while the Last Traded Quantity at Last Traded Price (LTQ@LTP) is 30, 210000.
The Fredun Pharmaceuticals operates within a circuit range of ₹1680.7-2521 – ₹1680.7-2521, with a Value of ₹2.07 CR. The Delivery Percentage for the day is 63.6%. Additionally, Fredun Pharmaceuticals currently falls under the No framework, and trades with a market lot size of 1.

Fredun Pharmaceuticals Fundamentals

View More
P/E Ratio

35.44

P/B Ratio

4.34

Div. Yield

0.03

Sector P/E

64.46

Sector P/B

3.52

Sec. Div. Yield

0.57

Fredun Pharmaceuticals Resistance and Support

Pivot 2123.62

Resistance

First Resistance

2177.24

Second Resistance

2253.62

Third Resistance

2307.24

Support

First Support

2047.24

Second Support

1993.62

Third Support

1917.24

Fredun Pharmaceuticals Shareholding Pattern

View More
  • 2016-17
  • 2018-19
  • 2019-20
  • 2020-21
  • 2021-22
  • 2022-23
  • 2023-24
  • 2024-25
  • 2025-26
  • 2026-27
Total Promoters
Segment
Percent

Total Promoters

44.17%

Mutual Fund

0%

Insurance

0%

Foreign Institutional Investors

1.06%

Domestic Institutional Investors

2.83%

Retail

51.94%

Others

0%

Total Promoters
MAR '26
44.17%

Fredun Pharmaceuticals Corporate Actions

DateAgenda
2026-02-09Quarterly Results
2025-11-08Quarterly Results
2025-09-25Preferential Issue of shares & Others
2025-07-30Quarterly Results
2025-05-30Audited Results & Dividend
2025-02-04Quarterly Results

Fredun Pharmaceuticals News

Fredun Pharmaceuticals Ltd - 539730 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

Fredun Pharmaceuticals expanded its manufacturing base with a new 40,000 sq. ft. facility in Palghar, Maharashtra, which is expected to be operational by October 2026. This expansion aims to enhance efficiency and scalability across pharmaceutical, nutraceutical, and veterinary product categories.
Apr 29 2026 11:04:00

Fredun Pharmaceuticals Ltd - 539730 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

Fredun Pharmaceuticals' promoter group acquired 40,000 shares by converting warrants. This transaction, executed on April 9, 2026, increased their voting stake to 44.57% and their overall holding (including remaining warrants) to 45.54% of the company's capital.
Apr 15 2026 09:04:00

Fredun Pharmaceuticals Ltd - 539730 - Disclosure Under Regulation 7(2) Of SEBI (Prohibition Of Insider Trading) Regulations, 2015.

Fredun Pharmaceuticals' Director, Daulat Nariman Medhora, acquired 4 lakh equity shares for ₹5 crore. This preferential allotment increased his shareholding from 25.78% to 26.32% as part of a warrant conversion.
Apr 13 2026 18:04:00

Fredun Pharmaceuticals Ltd - 539730 - Announcement under Regulation 30 (LODR)-Allotment

Fredun Pharmaceuticals Board approved the allotment of 40,000 equity shares to promoter Mrs. Daulat Nariman Medhora. These shares, valued at ₹1250 each, were issued upon conversion of previously allotted warrants, completing a ₹3.75 crore capital raise.
Apr 09 2026 18:04:00

Fredun Pharmaceuticals Ltd - 539730 - Board Meeting Outcome for Outcome Of Board Meeting Dated 09Th April, 2026

Fredun Pharmaceuticals Board approved the allotment of 40,000 equity shares to promoter Mrs. Daulat Nariman Medhora. These shares, valued at ₹1250 each, were issued upon conversion of previously allotted warrants, completing a ₹3.75 crore capital raise.
Apr 09 2026 18:04:00
Read More

About Fredun Pharmaceuticals

NSE : 0  
BSE : 539730  
ISIN : INE194R01017  

FREDUN PHARMACEUTICALS LIMITED is promoted by qualified andexperienced technocrats Mr. Nariman Medhora andDr.(Mrs.)Daulat Nariman Medhora.The promoters ventured into the business nine years ago andestablished a proprietary firm by the name and style ofD.N.Pharma for manufacture and export of pharmaceuticalformulations. The exports were mainly to Afghanistan WestAfrica D.N.Pharma has over 15 branded products covering awide range of applications as follows:--------------------------------------------------------------------------BRAND NAME DOSAGE FORM BULK DRUG APPLICATION--------------------------------------------------------------------------Neozoline Nasal Drop Xylometazoline Hydrochloride Decongestant DropsDolnacid Tablets Aluminium Hyrdoxide/Magnesium Antacid Tablets Hydroxide + SimethiconeNucee Drops Vitamin C Vitamin DropsDiarnil-N- Syrup Neomycin Sulphate Kaolin. Antidarrhoeal PectinNeogesic Cream Diethylamine Salicylate Anti-inflammatory Analgesic creamNeoprofane Tablet Ibuprofen Anti-inflammatory TabletsNervigesic Tablet Analgin/Vitamin B1 B6 B12 Neurological Problem--------------------------------------------------------------------------Their products are well received in the exports markets andhave a good demand. Since 1993 D.N.Pharma''s operations havebeen phased out with a view to switch over the business toFredun Pharmaceuticals Limited henceforth known as FPL).FPL has 50% stake in D.N.Pharma. The above mentionedproducts were being manufactured by D.N.Pharma on loanlicense basis from other manufacturers.Since the Registrar Of Companies did not permit theinclusion of the initials `D & N'' in the name D.N.Pharmafor the purpose of conversion of D.N.Pharma into a LimitedCompany it was decided to convert Fredun PharmaceuticalsPrivate Limited which had been incorporated on 8th June1987 to a Public Limited Company. Subsequently FredunPharmaceutical Private Limited was converted into a PublicLimited Company on 15th March 1994 and renamed as M/SFredun Pharmaceuticals Limited.FPL has its Registered Office at 26 Manoj IndustrialPremises G.D.Ambekar Marg Wadala Mumbai 400 031. It wasset up with the objective of providing facilities for themanufacturing and marketing of various pharmaceuticalformulations such as Tablets Capsules Dry-Syrups andOintments. The Company then set up a formulation plant atPalghar District Thane which is about 75 Kms from Mumbai.The Company will be manufacturing formulations for both theDomestic as well as the International Market.FPL has been carrying out the manufacturing operations onloan license for reputed Pharmaceutical companies likeCIPLA. It has also manufactured for some merchant exportersincluding Merind. The details as on 31st August are aslisted below:------------------------------------------------------------Brand Name TIC/S* Qty/Mn) Bulk drug L/L-M/E# L/E$------------------------------------------------------------Ferovita C 10.07 Ferrous M/E E FumarateYurovite C 4.50 Ferrous M/E E Fumarate-- T 2.40 Paracetamol M/E EChemicillin C 2.10 Ampicillin L/L EChemadol T 11.00 Paracetamol L/L EMetolar T 6.50 L/L LTheobid T 20.00 Theophylline L/L LIbugesic plus T 50.00 Ibuprofen L/L L Paracetamol-- T 12.00 Ferrous M/E E Fumarate-- T 17.00 Bisacodyl M/E E-- T 1.00 Pyrazinamide M/E ENovamox C 6.40 Amoxycillin L/L LPirox DT T 2.40 Piroxicam L/L LAmidol T 8.80 Paracetamol L/L EOxacilline C 0.50 Oxacillin L/L LNorflox TZ T 6.00 Norfloxacin L/L L Tinidazole------------------------------------------------------------* : T-Tablets C-Capsules S-Syrup# : L/L-Loan License M/E-Merchant Exports$ : L-Local E-ExportThe Company aims at producing high quality products. Theproducts are manufactured as per the Good ManufacturingPractices (GMP) Norms which assures quality safety andfreedom from harmful side effects.The GMP Norms cover a number of observance of basicprinciples and steps taken for the selection and trainingof personnel personal Industrial hygiene adequacy ofbuilding and premises production equipment including itsmaintenance and validation manufacturing and packagingprocesses including standard operating procedures qualityassurance raw and packing materials labelingdistribution warehousing and documentation.The Company has been granted the GMP certificate Food andDrugs Administration Maharashtra State and has applied forthe World Health Organisation (WHO) GMP. The Company alsohas a well equipped Quality Control Laboratory which hasthe most modern equipments and instruments to undertakechemical instrumental and microbiological analysis. Theplant is manned by a team of qualified and experiencedpersonnel. The firm has obtained all proper licenses suchas License to Manufacture for Sale from the Food and DrugAdministration of the Maharashtra State.The construction of the factory building was completed in1993. The manufacturing unit commenced commercialproduction in August 1994.

Read More

Fredun Pharmaceuticals Management

NamePosition
Daisy DsouzaNon Executive Independent Director
Sonal DesaiNon Executive Independent Director
View More

Fredun Pharmaceuticals FAQs

The Buying Price of Fredun Pharmaceuticals share is 2100 For live prices and instant trading, you can log in to your Choice trading account or open a Free Demat account with Choice.

To buy Fredun Pharmaceuticals stocks, log in to your Choice trading account. If you don’t have one, open a Choice Demat account. Then, add funds, search for Fredun Pharmaceuticals, choose your preferred order type, and place the trade.

The Price-to-earnings (P/E) ratio of Fredun Pharmaceuticals shares is 35.44. You can compare it with the sector average for relative valuation.

The Price to Book (P/B) ratio Fredun Pharmaceuticals shares is 4.34. Useful to assess the stock's value relative to its book value.

To assess Fredun Pharmaceuticals’s valuation compare Sector P/E, P/B which are 64.46 & 3.52 with sector averages, along with growth rates and financial metrics.

The Market Cap of Fredun Pharmaceuticals is 1000.35 CR. It indicates the company's size category and trading liquidity.

The 52 week high and low prices of Fredun Pharmaceuticals share price is 2200.00 & 666.00. They indicate price extremes, trading ranges, volatility measures, potential support/resistance, and price momentum.

Fredun Pharmaceuticals belongs to the Healthcare sector.

Invest with Zero-Cost Demat Account

Zero AMC for First Year
Free Research Calls
₹ 0 Trade & Call Fee
Zero-Cost